"Hypercholesterolemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Descriptor ID |
D006937
|
| MeSH Number(s) |
C18.452.584.500.500.396
|
| Concept/Terms |
Hypercholesterolemia- Hypercholesterolemia
- Hypercholesterolemias
- High Cholesterol Levels
- Cholesterol Level, High
- Cholesterol Levels, High
- High Cholesterol Level
- Level, High Cholesterol
- Levels, High Cholesterol
- Elevated Cholesterol
- Cholesterol, Elevated
- Cholesterols, Elevated
- Elevated Cholesterols
- Hypercholesteremia
- Hypercholesteremias
|
Below are MeSH descriptors whose meaning is more general than "Hypercholesterolemia".
Below are MeSH descriptors whose meaning is more specific than "Hypercholesterolemia".
This graph shows the total number of publications written about "Hypercholesterolemia" by people in this website by year, and whether "Hypercholesterolemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 4 | 0 | 4 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 1 | 0 | 1 |
| 2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypercholesterolemia" by people in Profiles.
-
Safety and Tolerability of Inclisiran for?Treatment of Hypercholesterolemia in?7 Clinical Trials. J Am Coll Cardiol. 2023 12 12; 82(24):2251-2261.
-
Familial hypercholesterolemia: The nexus of endothelial dysfunction and lipoprotein metabolism in COVID-19. Curr Opin Lipidol. 2023 06 01; 34(3):119-125.
-
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia. Curr Opin Lipidol. 2021 08 01; 32(4):213-218.
-
New cholesterol targets for patients at high or very high cardiovascular risk and the indications for PCSK9 inhibitors. S Afr Med J. 2020 Oct 28; 110(11):13126.
-
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med. 2020 04 16; 382(16):1507-1519.
-
PCSK9 Inhibitors: From Nature's Lessons to Clinical Utility. Endocr Metab Immune Disord Drug Targets. 2020; 20(6):840-854.
-
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019 10 29; 74(17):2132-2146.
-
Consistent LDL-C response with evolocumab among patient subgroups in PROFICIO: A pooled analysis of 3146 patients from phase 3 studies. Clin Cardiol. 2018 Oct; 41(10):1328-1335.
-
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol. 2017 06 01; 2(6):598-607.
-
Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes. HIV Med. 2017 09; 18(8):595-603.